Replies to post #150703 on Biotech Values

[genisi]

BLRX still says their MOA is to block virus induced autophagy....

I've looked for patents related to HCV treatment and the French scientist from whom BLRX got BL-8020 and BL-8030 and perhaps the idea is to coformulate the PI with hydroxychloroqune. See:

http://www.surechem.org/index.php?Action=document&docId=2053015&db=WOPCT